EU/3/13/1208

About

On 13 November 2013, orphan designation (EU/3/13/1208) was granted by the European Commission to Katairo GmbH, Germany, for soraprazan for the treatment of Stargardt's disease.

Key facts

Active substance
Soraprazan
Disease / condition
Treatment of Stargardt's disease
Date of decision
13/11/2013
Outcome
Positive
Orphan decision number
EU/3/13/1208

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Katairo GmbH
Lederstrasse 21
72127 Kusterdingen
Germany
Tel. +49 7071 5496184
Fax +49 7071 5496183
E-mail: info@katairo.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating